Entrada Therapeutics, Inc.

TRDA · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders12.2%

Institutions82.8%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$25.42M	$210.78M	$129.01M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$157.90M	$47.01M	-$3.16M	-$97.25M	-$51.13M
Operating income as a percentage of revenue.	-621.1%	22.3%	-2.5%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$143.75M	$65.63M	-$6.68M	-$94.62M	-$51.16M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.47	$1.76	$-0.20	$-3.02	$-8.16
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.47	$1.68	$-0.20	$-3.02	$-8.16

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$90.39M	$101.21M	$67.60M	$45.16M	$291.10M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$377.38M	$526.32M	$469.19M	$252.06M	$305.83M
Everything the company owes — debt, unpaid bills, and other obligations.	$71.25M	$97.64M	$226.83M	$39.50M	$7.12M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$306.13M	$428.68M	$242.36M	$212.55M	$298.72M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$128.51M	-$41.56M	$139.80M	-$93.79M	-$50.86M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.04M	$3.16M	$5.61M	$2.89M	$4.58M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$129.55M	-$44.72M	$134.19M	-$96.67M	-$55.44M

	You	Peer avg
Revenue Growth	-53.9%	+303.2%
ROE	-54.1%	-114.0%

Entrada Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison